Abstract 5377
Background
Genomic profiling of cell-free ctDNA is a non-invasive method to guide personalised medicine. We assessed the utility of ctDNA in routine clinical practice where tumor biopsy were impossible to obtain, tissue insufficient or clinically contraindicated.
Methods
A 73-gene panel using ctDNA NGS (Guardant360®) was offered to consecutive stage 4 NSCLC patients - results were discussed in our Genomics Review Board to assess potential actionable alterations and enrolment into clinical trials.
Results
50 pts (37F:13M; median 64 yrs) participated. ctDNA was obtained in 6 treatment (Tx) naïve patients (pts), in 22pts post 1st-line, in 7pts post 2nd-line, in 5 pts post 3rd-line and in 5 pts with > 4 Tx – in 5 pts prior Tx was unknown. EGFR status at Dx was known in 40 (23mt/17wt) and unknown in 10 pts. Of the pts with known EGFRmt, 6 pts progressed on gefitinib, 7 pts on afatinib, 8 pts on erlotinib, and 2 pts did not receive prior anti-EGFR Tx. ctDNA testing confirmed EGFRmt in 14 pts. In 9 pts with previously Bx-proven EGFRmt ctDNA did not detect an EGFRmt - the lag time between Bx and ctDNA was a median of 18 months (range 1-94 months). New EGFRmt were found in 3 pts with unknown EGFR status allowing access to anti-EGFR Tx. Acquired T790M were found in 4 pts progressing on prior anti-EGFR Tx, those pts received osimertinib. In 1 pt with ctDNA T790M+, a concomitant solid Bx was T790M-. Other alterations were, TP53 (n = 23), KRAS (n = 7), ERBB2 (n = 1), NTRK1 (n = 2), NF1 (n = 12), MET (n = 7), BRAF (n = 5), PIK3CA (n = 5), ALK (n = 2), BRCA1 (n = 1), BRCA2 (n = 2), PDGFRA (n = 3), AR (n = 4), TERT (n = 3), CDK4 (n = 3), CDK6 (n = 3), FGFR2 (n = 2), STK11 (n = 2), KIT (n = 2), SMAD4 (n = 3), CDH1 (n = 1), NOTCH1 (n = 2), RB1 (n = 3), TSC1 (n = 1), ERBB1(n = 1), MTOR (n = 3), MYC (n = 3), ARAF (n = 1), GNAS (n = 1), AKT1(n = 1), CDKN2A (n = 2), ARID1A (n = 2), CTNNB1 (n = 1), CCNE1 (n = 1). Critical review in the GRB meeting was fundamental in interpreting the genetic alterations of significance.
Conclusions
We confirm the feasibility and clinical utility of ctDNA testing in NSCLC patients where tumor biopsies were insufficient, impossible or contraindicated and identified 7 pts (14%) who based on their ctDNA results received 1st/2nd-line anti-EGFR treatment, several more were recommended for clinical trials.
Clinical trial identification
Legal entity responsible for the study
Sarah Cannon Research Institute.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
P. Bennett: Employee: Sarah Cannon Molecular Diagnostics. I. Faull, R.B. Lanman: Employee: Guardant. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract